SEC Form 4 · accession 0001104659-16-163884
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anne Vanlent
Director
Period of report
Dec 22, 2016
Accepted (ET)
Dec 27, 2016 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $8.65 | Dec 22, 2016 | A | 9,600 | A | — | Dec 22, 2026 | Common Shares | 9,600 | 9,600 | D |
Explanation of responses
- F1Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
- F2The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date.